ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

alpha 1-Antitrypsin

Also written as “Alpha-1 MP”, “GLASSIA” and “Alpha1-proteinase inhibitor”.

Its studies are mostly in alpha 1-Antitrypsin Deficiency · Pulmonary Disease, Chronic Obstructive · Pulmonary Emphysema · Graft vs Host Disease · Diabetes Mellitus, Type 1, led by 4 companies.

Drug pageAlpha 1-Antitrypsin: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Feb 20, 200626 company-led studies, 2 open or runningNext primary completion: Sep 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Grifolsits history only131 open or runningphase 3since Feb 20, 2006Sep 12, 2005Sep 2028phase 3 · NCT02796937
Takeda70 open or runningphase 4since Nov 3, 2006Nov 3, 2006none ahead
CSLits history only31 open or runningphase 4since Dec 2, 2005Dec 2, 2005Sep 15, 2033phase 4 · NCT07326592
Kamadaits history only30 open or runningphase 3since Dec 17, 2019Feb 24, 2011none ahead

Also a collaborator on its studies: Baxalta Innovations GmbH, now part of Shire.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Takeda only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 3, 2006First study: phase 4 study in alpha 1-Antitrypsin DeficiencyFirst studyNCT00396006 · 21 enrolled · Australia, New Zealand
  2. Jul 23, 2012Phase 4 study in alpha 1-Antitrypsin DeficiencyNCT01651351 · 30 enrolled · United States
  3. Aug 14, 2015Phase 3 study in alpha 1-Antitrypsin DeficiencyNCT02525861 · 34 enrolled · United States, Canada
  4. Mar 23, 2016Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT02722304 · 7 enrolled · United States, Australia, Canada
  5. Oct 24, 2016Phase 3 study in Graft vs Host DiseaseNCT02956122 · 1 enrolled · United States
  6. Jun 17, 2020Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT04440488
  7. Jun 17, 2022Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT05466747

TargetBeta

ELANE →read by rule
“Leukocyte elastase inhibitor”ChEMBL 37, by rule

Studies

All 7 Takeda leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05466747Pulmonary Disease, Chronic Obstructive4WithdrawnApr 26, 20270
NCT04440488Pulmonary Disease, Chronic Obstructive4WithdrawnSep 12, 20250
NCT02956122Graft vs Host Disease · United States3TerminatedMay 3, 20181
NCT02722304Pulmonary Disease, Chronic Obstructive · United States, Australia, Canada3TerminatedSep 14, 20187
NCT02525861alpha 1-Antitrypsin Deficiency · United States, Canada3CompletedJul 29, 202034
NCT01651351alpha 1-Antitrypsin Deficiency · United States4CompletedJan 16, 201330
NCT00396006alpha 1-Antitrypsin Deficiency · Australia, New Zealand4CompletedDec 14, 200721

How it is read

Names in the registry

  • “Alpha-1 MP”, 5 entries
  • “GLASSIA”, 2 entries
  • “Alpha1-proteinase inhibitor”, 2 entries
  • “Alpha1-Proteinase Inhibitor (Human)”, 2 entries
  • “CE1226”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.